Novartis Advances Vanrafia Phase III Data and Plans Texas Radioligand Therapy Facility

Novartis is back in focus after final Phase III ALIGN data showed its drug Vanrafia slowed kidney function decline in adults with IgA nephropathy, reinforcing earlier approvals and helping spark fresh investor interest. The company also announced plans to build its latest radioligand therapy (RLT) manufacturing site in Denton, Texas, as part of the Swiss drugmaker's efforts to expand its U.S. operations.

The new 46,000-square-foot facility is expected to become operational in 2028. The Vanrafia update lands on top of a strong run for Novartis, with a 30 day share price return of 8.25% and a 90 day share price return of 18.30%. This has contributed to a 1 year total shareholder return of 35.91% and a 5 year total shareholder return of 102.00%, suggesting momentum has been building over both shorter and longer periods as recent earnings, a proposed dividend increase and radioligand supply deals keep the stock in focus.

With the shares near recent highs and trading at a reported 50% discount to one intrinsic value estimate, despite strong multi year returns, the most followed narrative puts Novartis' fair value at CHF113.58, below the last close of CHF125.14. The current P/E of 22.2x sits below the European pharmaceuticals average of 24.2x, well under peer levels at 86.8x, and beneath a fair ratio of 38.5x.

Novartis' robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies, potentially accelerating future earnings and margin growth as new high-value products launch. However, steady sales assumptions could be knocked off course if key drugs face faster generic pressure or if pricing reforms tighten more quickly in major markets.